trans-4-Methyl-cyclohexancarbonsaeurenitril | 40636-31-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: trans-4-Methyl-cyclohexancarbonsaeurenitril
• 英文别名: trans-4-Methyl-cyclohexancarbonitril
• CAS: 40636-31-5
• 化学式: C₈H₁₃N
• 分子量: 123.198
• InChiKey: QUDYVSRXUSHARR-ZKCHVHJHSA-N

物化性质

• 沸点：
  208.8±9.0 °C(Predicted)
• 密度：
  0.89±0.1 g/cm3(Predicted)

文献信息

• SUBSTITUTED HETEROCYCLIC COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TRKA) INHIBITORS
  申请人：Dr. Reddy's Laboratories Ltd.

  公开号：US20150005280A1

  公开（公告）日：2015-01-01

  The present application relates to a series of substituted pyrazolo[1,5-a]pyridine compounds, their use as tropomyosin receptor kinase (Trk) family protein kinase inhibitors, method of making and pharmaceutical compositions comprising such compounds.

  本申请涉及一系列取代吡唑并[1,5-a]吡啶化合物，其作为肌浆蛋白受体激酶（Trk）家族蛋白激酶抑制剂的用途，制备方法以及包含这些化合物的药物组合物。
• TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
  申请人：Babu Srinivasan

  公开号：US20110201593A1

  公开（公告）日：2011-08-18

  The invention provides novel compounds of formula I having the general formula: wherein R 1 , R 2 , R 3 , X and Y are as described herein. Accordingly, the compounds may be provided in pharmaceutically acceptable compositions and used for the treatment of immunological or hyperproliferative disorders.

  本发明提供了具有以下一般式的新化合物I： 其中R1、R2、R3、X和Y如本文所述。因此，这些化合物可以在药学上可接受的组合物中提供，并用于治疗免疫或过度增生性疾病。
• THERAPEUTIC COMPOUNDS AND USES THEREOF
  申请人：Constellation Pharmaceuticals, Inc.

  公开号：US20160158207A1

  公开（公告）日：2016-06-09

  The present invention relates to compounds of formula (I) or formula (II): and to salts thereof, wherein R 1 -R 4 of formula (I) and R 1 -R 3 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.

  本发明涉及公式（I）或公式（II）的化合物及其盐，其中公式（I）的R1-R4和公式（II）的R1-R3具有以下定义的任何值，以及其组合物和用途。这些化合物可用作CBP和/或EP300的抑制剂。还包括含有公式（I）或公式（II）的化合物或其药学上可接受的盐的制药组合物，以及使用这些化合物和盐治疗各种CBP和/或EP300介导的疾病的方法。
• PIPERIDINE OXADIAZOLE AND THIADIAZOLE OREXIN RECEPTOR ANTAGONISTS
  申请人：MERCK SHARP & DOHME CORP.

  公开号：US20170313693A1

  公开（公告）日：2017-11-02

  The present invention is directed to piperidine oxadiazole and thiadiazole orexin compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
• PROTEASOME ACTIVITY ENHANCING COMPOUNDS
  申请人：Proteostasis Therapeutics, Inc.

  公开号：US20210188802A1

  公开（公告）日：2021-06-24

  The present invention is directed to compounds that inhibit Usp14, compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.